# Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

> **NCT01361711** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 53 (actual)

## Conditions studied

- Stage I Chronic Lymphocytic Leukemia
- Stage II Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage IV Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** ofatumumab
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT01361711
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-06
- **Primary completion:** 2015-08-17
- **Final completion:** 2027-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01361711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01361711, "Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01361711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*